Abstract
OBJECTIVES:To present some cases of patients with Moyamoya syndrome secondary to diverse etiologies, and, based on them, to review general aspects of the clinical picture. Supported on two cases, the hypothesis of a new mechanism is proposed.
MATERIALS AND METHODS:Four clinical cases of Moyamoya syndrome are described, identified in the city of Medellín, Colombia, with their respective images and the evolution of their condition. Based on two of the cases, in which the syndrome was triggered after the implantation of a flow-diverter stent, a new etiology is proposed.
RESULTS:In two cases, the implantation of a flow-diverter stent was identified as the trigger of the Moyamoya picture. In one case the primary disease was type 1 neurofibromatosis; in the fourth case it was not possible to identify the cause of the syndrome. None of the patients presented neurological compromise despite severe arterial damage.
CONCLUSIONS:Moyamoya syndrome (MMS), rather than an independent entity, should be understood as a compensatory and defensive mechanism in response to the deprivation of blood flow in the anterior cerebral circulation, which protects patients from ischemic cerebrovascular events. Implantation of flow-diverter stents, as a method of treatment of some cerebral aneurysms, is projected in time as an important cause of this syndrome.
References
Labour H. Guidelines for Diagnosis and Treatment of Moyamoya Disease (Spontaneous Occlusion of the Circle of Willis). Neurol Med Chir. 2012;52(5): 245-66.
Han C, Yang W Zhang H, Ye T, Duan L. Clinical characteristics and long-term outcomes of moyamoya syndrome associated with neurofibromatosis type 1. J Clin Neurosci. 2015.22(2):286-90. https://doi.org/10.10167j.jocn.2014.05.046.
Scott RM, Smith ER. Moyamoya disease and Moyamoya syndrome. N Engl J Med. 2009;360:1227-37. https://doi.org/10.1056/NEJMra0804622.
J. H. Phi, D. Ph, K. Wang, D. Ph, J. Y Lee, D. Ph, S. Kim, D. Ph. Moyamoya syndrome : a window of Moyamoya disease. J Korean Neurosurg Soc. 2015;57(6):408-14. https://doi.org/10.3340/jkns.2015.57.6.408.
Fukui M. Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis ('moyamoya' disease). Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan. Clin Neurol Neurosurg. 1997;99; Suppl 2:S238-40.
Espinosa E, Ortiz A, Ardila S, Cabarcas L, Mancilla N. Moyamoya syndrome and disease Caso clínico. Acta Neurol Colomb. 2011:27(3):165-171.
Mineharu Y, Liu W, Inoue K. Autosomal dominant moyamoya disease maps to chromosome 17q25.3. Neurology. 2008;70(24 Pt 2):2357-63. https://doi.org/10.1212/01.wnl.0000291012.49986.f9.
Smith ER, Scott RM. Moyamoya: epidemiology, presentation, and diagnosis. Neurosurg Clin N Am. 2010;21(3):543-51. https://doi.org/10.1016/j.nec.2010.03.007.
Kim SK, Cho BK, Phi JH, Lee JY, Chae JH, Kim KJ, et al. Pediatric Moyamoya disease: An analysis of 410 consecutive cases. Ann Neurol. 2010;68(1):92-101. https://doi.org/10.1002/ana.21981.
Fujimura M, Bang Y, Kim S. Moyamoya Disease. Front Neurol Neurosci. 2016;40:204-20. https://doi.org/10.1159/000448314.
Im SH, Cho CB, Joo WI, Chough CK, Park HK, Lee KJ, et al. Prevalence and epidemiological features of moyamoya disease in Korea. J Cerebrovasc Endovasc Neurosurg. 2012;14(2):75-8. https://doi.org/10.7461/jcen.2012.14.2.75.
Vargas R, Sánchez H, Suárez Chaparro SJ, Jiménez Pena OM. Enfermedad de moyamoya : a propósito de un caso. Acta Neurol Colomb. 2016; 32(4): 310-13. http://dx.doi.org/10.22379/24224022113.
Africano H, Moreno R. Reporte de dos casos de moyamoya en el Hospital Universitario Los Comuneros de Bucaramanga (Santander) Report of two cases of Moyamoya disease at the Los Comuneros University Hospital. Acta Neurol Colomb. 2015;31(3):310-17.
Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives. Lancet Neurol. 2008;7(11):1056-66. http://dx.doi.org/10.1016/S1474-4422(08)70240-0.
Suzuki J, Takaku A. Cerebrovascular "Moyamoya" disease: disease showing abnormal net-like vessels in base of brain. Arch Neurol 1969; 20:288-99.
Jett K, Friedman JM. Clinical and genetic aspects of neurofibromatosis 1. Genet Med. 2010;12(1):1-11. http://dx.doi.org/10.1097/GIM.0b013e3181bf15e3.
Yamauchi T, Tada M, Houkin K, Tanaka T, Nakamura Y, Kuroda S, et al. Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke. 2000;31(4):930-5.
Koc F, Yerdelen D, Koc Z. Neurofibromatosis type 1 association ,with moyamoya disease. Int J Neurosci. 2008;118(8):1157-63. http://dx.doi.org/10.1080/00207450801898279.
H. S. Pedro, S. D. M. Interna, H. S. Pedro, L. Rioja, H. San. Síndrome de Moyamoya de aparición en la edad adulta en una paciente con neurofibromatosis tipo 1. Neurol. 2016;31:7-9.
Kawaguchi S, Sakaki T, Morimoto T, Kakizaki T, Kamada K. Characteristics of intracranial aneurysms associated with moyamoya disease. A review of 111 cases. Acta Neurochir. (Wien). 1996;138(11):1287-94.
Rea D, Brandsema JF, Armstrong D, Parkin PC, deVeber G, MacGregor D, et al. Cerebral arteriopathy in children with neurofibromatosis type 1. Pediatrics. 2009;124(3):e476-83. http://dx.doi.org/10.1542/peds.2009-0152.
Rosser TL, Vezina G, Packer RJ. Cerebrovascular abnormalities in a population of children "with neurofibromatosis type 1. Neurology. 2005 Feb 8;64(3):553-5. http://dx.doi.org/10.1212/01. WNL.0000150544.00016.69.
Ghosh PS, Rothner AD, Emch TM, Friedman NR, Moodley M. Cerebral vasculopathy in children with neurofibromatosis type 1. J. Child Neurol. 2013 Jan;28(1):95-101. http://dx.doi. org/10.1177/0883073812441059.
Cairns AG, North KN. Cerebrovascular dysplasia in neurofibromatosis type 1. J Neurol Neurosurg Psychiatry. 2008;79(10):1165-70. http://dx.doi.org/10.1136/jnnp.2007.136457.
Norton KK, Xu J, Gutmann DH. Gutmann. Expression of the neurofibromatosis I gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle. Neurobiol Dis. 1995;2(1):13-21. http://dx.doi.org/10.1006/nbdi.1995.0002.
Ullrich NJ, Robertson R, Kinnamon DD, Scott RM, Kieran MW, Turner CD, et al. Moyamoya Following Cranial Irradiation for Primary Brain Tumors in Children. Neurology 2007.20;68(12):932-8. http://dx.doi.org/10.1212/01.wnl.0000257095.33125.48.
Briganti F, Napoli M, Leone G, Marseglia M, Mariniello G, Caranci F, et al. Treatment of intracranial aneurysms by flow diverter devices: Long-term results from a single center. Eur J Radiol. 2014;83(9).1683-90. https://doi.org/10.1016/j.ejrad.2014.05.029.
Patzig M, Forbrig R, Ertl L, Brückmann H, Fesl G. Intracranial Aneurysms Treated by Flow-Diverting Stents: Long-Term Follow-Up with Contrast-Enhanced Magnetic Resonance Angiography. Cardiovasc Intervent Radiol. 2017;40(11):1713-22. https://doi.org/10.1007/s00270-017-1732-z.
Becske T, Kallmes DF, Saatci I, McDougall CG, Szikora I, Lan-zino G, et al. Pipeline for uncoilable or failed aneurysms: results from a multicenter clinical trial. Radiology. 2013;267(3):858-68. https://doi.org/10.1148/radiol.13120099.
Cohen JE, Gomori JM, Moscovici S, Leker RR, Itshayek E. Delayed complications after flow-diverter stenting: Reactive in-stent stenosis and creeping stents. J Clin Neurosci. 2014;21(7):1116-22. https://doi.org/10.1016/j.jocn.2013.11.010.
Zhou G, Su M, Yin YL, Li MH. Complications associated with the use of flow-diverting devices for cerebral aneurysms: a systematic review and meta-analysis. Neurosurg Focus. 2017;42(6):E17. https://doi.org/10.3171/2017.3.FOCUS16450.
G Roach ES, Golomb MR, Adams R, Biller J, Daniels S, Deveber G, et al. Management of stroke in infants and children: A scientific statement from a special writing group of the american heart association stroke council and the council on cardiovascular disease in the young. Stroke. 2008 Sep;39(9):2644-91. https://doi.org/10.1161/STROKEAHA.108.189696.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.